Also listed on Mesoblast, Inc., an earlier holder on the record. The recorded assignments below show how it moved.
Term ends Sep 14, 2027 · High confidence
20-year base term ends Jan 5, 2027
Held by Mesoblast International Sàrl
Filed Nov 2, 2020 as application 17/087,124 · Granted Nov 21, 2023
Base term plus 252 days of patent term adjustment (USPTO delay)
Today
2007
2027
Clock starts
Jan 5, 2007
Jan 5, 2007
Term ends
Sep 14, 2027
Sep 14, 2027
Granted
Nov 21, 2023
Nov 21, 2023
base term
patent term adjustment
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
252
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
None
Terminal disclaimer
No disclaimer on this record.
None due
Maintenance fees
This term ends before the first maintenance fee's grace period does, 4 years from grant, so no fee can end it early.
70
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term runs 252 days past its 20-year base term on prosecution delay. No maintenance fee can end this term early. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jan 5, 2007, when application PCT/US2007/000274, the earliest non-provisional in its chain, was filed (this one was filed Nov 2, 2020) | Jan 5, 2027 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +252 days, USPTO patent term adjustment record | Sep 14, 2027 | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | No maintenance fee can end the term early | In force | High confidence |
| Computed term end | The steps above, in order | Sep 14, 2027 | High confidence |
This family
| US 7,153,500 | Term ended Jan 2020 | Jan 2020 |
| US 6,761,887 | Term ended Nov 2019 | Nov 2019 |
| US 6,875,430 | Term ended no later than Mar 2019 | no later than Mar 2019 |
| Application 09/937,974 | Abandoned not computed | not computed |
| US 7,029,666 | Term ended no later than Mar 2019 | no later than Mar 2019 |
| Application 10/127,737 | Abandoned not computed | not computed |
| Application 60/384,759 | Pending not computed | not computed |
| Application 10/278,148 | Abandoned not computed | not computed |
8 of 70 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Dec 8, 2020 Reel 54578, frame 101 | Danilkovitch, Alla; Carter, Diane; Tyrell, Alicia; Bubnic, Simon; Marcelino, Michelle; Monroy, Rodney | Osiris Therapeutics, Inc. | Assignment of Assignor's Interest |
| Dec 8, 2020 Reel 54578, frame 299 | Osiris Therapeutics, Inc. | Mesoblast International Sàrl | Assignment of Assignor's Interest |
| Dec 10, 2021 Reel 58957, frame 447 | Mesoblast Limited Acn 109 431 870; Mesoblast UK Limited; Mesoblast, Inc. (Formerly Known as Angioblast, Inc.); Mesoblast International Sàrl | Oaktree Fund Administration, LLC | Security Interest |
| Jan 2, 2026 Reel 74174, frame 183 | Oaktree Fund Administration, LLC, as Agent | Mesoblast Limited; Mesoblast UK Limited; Mesoblast, Inc. (Formerly Known as Angioblast, Inc.); Mesoblast International Sàrl | Release of Security Interest in Intellectual Property |
| Jan 2, 2026 reel/frame not recorded | Oaktree Fund Administration, LLC, as Agent | Mesoblast Limited | Release of Security Interest in Intellectual Property |
| Jan 2, 2026 reel/frame not recorded | Oaktree Fund Administration, LLC, as Agent | Mesoblast UK Limited | Release of Security Interest in Intellectual Property |
| Jan 2, 2026 reel/frame not recorded | Oaktree Fund Administration, LLC, as Agent | Mesoblast, Inc. (Formerly Known as Angioblast, Inc.) | Release of Security Interest in Intellectual Property |
| Jan 2, 2026 reel/frame not recorded | Oaktree Fund Administration, LLC, as Agent | Mesoblast International Sàrl | Release of Security Interest in Intellectual Property |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Sep 2027
Term ends Sep 14, 2027. No further fees fall due before then
Note
The 252 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Citations
5
later US patents cite this one
That is top 25% of utility patents granted in 2023 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.